Intuitive Surgical (NASDAQ:ISRG) SVP Mark Brosius Sells 648 Shares

Intuitive Surgical, Inc. (NASDAQ:ISRG) SVP Mark Brosius sold 648 shares of Intuitive Surgical stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $488.10, for a total transaction of $316,288.80. Following the completion of the sale, the senior vice president directly owned 5,916 shares of the company’s stock, valued at approximately $2,887,599.60. This trade represents a 9.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Mark Brosius also recently made the following trade(s):

• On Thursday, March 5th, Mark Brosius sold 648 shares of Intuitive Surgical stock. The shares were sold at an average price of $495.20, for a total value of $320,889.60.
• On Wednesday, March 4th, Mark Brosius sold 2,362 shares of Intuitive Surgical stock. The stock was sold at an average price of $498.68, for a total value of $1,177,882.16.
• On Monday, December 15th, Mark Brosius sold 464 shares of Intuitive Surgical stock. The stock was sold at an average price of $548.49, for a total value of $254,499.36.
• On Friday, December 12th, Mark Brosius sold 4,500 shares of Intuitive Surgical stock. The shares were sold at an average price of $547.36, for a total value of $2,463,120.00.

Intuitive Surgical Price Performance

Shares of NASDAQ:ISRG traded down $4.48 during trading on Thursday, reaching $496.70. 1,541,063 shares of the stock were exchanged, compared to its average volume of 2,057,887. Intuitive Surgical, Inc. has a 1-year low of $425.00 and a 1-year high of $603.88. The stock has a fifty day moving average of $525.02 and a two-hundred day moving average of $512.10. The firm has a market cap of $176.39 billion, a price-to-earnings ratio of 62.95, a price-to-earnings-growth ratio of 3.83 and a beta of 1.66.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 EPS for the quarter, beating analysts’ consensus estimates of $2.27 by $0.26. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. The business had revenue of $2.87 billion during the quarter, compared to analyst estimates of $2.72 billion. During the same quarter in the previous year, the business posted $2.21 EPS. Intuitive Surgical’s quarterly revenue was up 18.8% on a year-over-year basis. Sell-side analysts forecast that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Hedge Funds Weigh In On Intuitive Surgical

Several institutional investors have recently added to or reduced their stakes in ISRG. Vanguard Group Inc. grew its position in shares of Intuitive Surgical by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 33,599,661 shares of the medical equipment provider’s stock valued at $15,026,776,000 after acquiring an additional 263,828 shares during the period. State Street Corp lifted its stake in Intuitive Surgical by 1.0% in the fourth quarter. State Street Corp now owns 15,701,591 shares of the medical equipment provider’s stock valued at $8,892,753,000 after purchasing an additional 162,264 shares during the last quarter. Geode Capital Management LLC lifted its stake in Intuitive Surgical by 1.4% in the second quarter. Geode Capital Management LLC now owns 8,188,685 shares of the medical equipment provider’s stock valued at $4,429,590,000 after purchasing an additional 109,904 shares during the last quarter. Capital World Investors grew its holdings in Intuitive Surgical by 1.7% during the fourth quarter. Capital World Investors now owns 7,856,018 shares of the medical equipment provider’s stock valued at $4,449,491,000 after purchasing an additional 127,526 shares during the period. Finally, Norges Bank purchased a new stake in Intuitive Surgical in the fourth quarter worth $2,856,987,000. Institutional investors own 83.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Citigroup reissued a “neutral” rating and set a $590.00 price objective (down from $635.00) on shares of Intuitive Surgical in a report on Friday, January 23rd. HSBC upped their price target on Intuitive Surgical from $644.00 to $653.00 and gave the stock a “buy” rating in a report on Monday, January 26th. UBS Group set a $570.00 price target on Intuitive Surgical and gave the company a “neutral” rating in a research report on Tuesday, February 24th. Royal Bank Of Canada lifted their price objective on shares of Intuitive Surgical from $625.00 to $650.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. Finally, Zacks Research upgraded shares of Intuitive Surgical from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 19th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and a consensus price target of $615.86.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.